胸椎旁阻滞与肋间神经阻滞对比胸段硬膜外阻滞在肺手术中的随机非劣效试验
该随机临床试验在荷兰和比利时11家医院纳入450例胸腔镜解剖性肺切除术患者,比较连续胸椎旁阻滞(PVB)和单次肋间神经阻滞(ICNB)与胸段硬膜外镇痛(TEA)的镇痛效果。意向性分析纳入389例,结果显示仅ICNB在疼痛控制上非劣效于TEA,PVB劣于TEA;ICNB和PVB均减少阿片类药物用量并改善活动能力,且ICNB组住院时间更短。
要点
- ICNB在胸腔镜肺切除术后镇痛非劣效于TEA(ITT UL 16.1%)。
- PVB镇痛劣于TEA(ITT UL 22.4%),未达非劣效界值。
- ICNB和PVB均减少阿片用量、改善活动,ICNB住院更短。
核心结论
- 胸腔镜解剖性肺切除术后,仅ICNB在镇痛上非劣效于TEA,可作为TEA的替代选择。
研究设计与样本
- 随机临床试验,按1:1:1比较PVB、ICNB与TEA,在荷兰和比利时11家医院进行。
- 2021年3月5日至2023年9月5日纳入450例胸腔镜解剖性肺切除术患者,389例纳入意向性分析。
主要发现
- 疼痛评分≥4分的平均比例:TEA组20.7%(95%CI 16.5%-24.9%),PVB组35.5%(95%CI 30.1%-40.8%),ICNB组29.5%(95%CI 24.6%-34.4%)。
- PVB对比TEA疼痛非劣效性未成立(ITT UL 22.4%;PP UL 23.1%),ICNB对比TEA非劣效成立(ITT UL 16.1%;PP UL 17.0%)。
- QoR-15评分各组相似:TEA组104.96(20.47),PVB组106.06(17.94,P=.641),ICNB组106.85(21.11,P=.47)。
- ICNB和PVB较TEA显著减少阿片类药物用量并改善活动能力,并发症无显著差异,ICNB组住院时间更短。
临床怎么用
- 对于胸腔镜解剖性肺切除术患者,可考虑单次ICNB作为TEA的替代镇痛方案。
- 选择ICNB替代TEA时需权衡风险与获益,个体化制定镇痛策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Effective pain control after thoracic surgery is crucial for enhanced recovery. While thoracic epidural analgesia (TEA) traditionally ensures optimal analgesia, its adverse effects conflict with the principles of enhanced recovery after thoracic surgery. High-quality randomized data regarding less invasive alternative locoregional techniques are lacking. OBJECTIVE: To evaluate the efficacy of continuous paravertebral block (PVB) and a single-shot intercostal nerve block (ICNB) as alternatives to TEA. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial compared PVB and ICNB vs TEA (1:1:1) in patients undergoing thoracoscopic anatomical lung resection at 11 hospitals in the Netherlands and Belgium, enrolled from March 5, 2021, to September 5, 2023. The study used a noninferiority design for pain and a superiority design for quality of recovery (QoR). INTERVENTIONS: Continuous PVB and single-shot ICNB. MAIN OUTCOMES AND MEASURES: Primary outcomes were pain, defined as mean proportion of pain scores 4 or greater during postoperative days (POD) 0 through 2 (noninferiority margin for the upper limit [UL] 1-sided 98.65% CI, 17.5%), and QoR, assessed with the QoR-15 questionnaire at POD 1 and 2. Secondary measures included opioid consumption, mobilization, complications, and hospitalization. RESULTS: A total of 450 patients were randomized, with 389 included in the intention-to-treat (ITT) analysis (mean [SD] age, 66 [9] years; 208 female patients [54%] and 181 male [46%]). Of these 389 patients, 131 received TEA, 134 received PVB, and 124 received ICNB. The mean proportions of pain scores 4 or greater were 20.7% (95% CI, 16.5%-24.9%) for TEA, 35.5% (95% CI, 30.1%-40.8%) for PVB, and 29.5% (95% CI, 24.6%-34.4%) for ICNB. While PVB was inferior to TEA regarding pain (ITT: UL, 22.4%; analysis per-protocol [PP]: UL, 23.1%), ICNB was noninferior to TEA (ITT: UL, 16.1%; PP: UL, 17.0%). The mean (SD) QoR-15 scores were similar across groups: 104.96 (20.47) for TEA, 106.06 (17.94; P = .641) for PVB (P = .64 for that comparison), and 106.85 (21.11) for ICNB (P = .47 for that comparison). Both ICNB and PVB significantly reduced opioid consumption and enhanced mobility compared with TEA, with no significant differences in complications. Hospitalization was shorter in the ICNB group. CONCLUSIONS AND RELEVANCE: After thoracoscopic anatomical lung resection, only ICNB provides noninferior pain relief compared with TEA. ICNB emerges as an alternative to TEA, although risks and benefits should be weighed for optimal personalized pain control. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05491239.
引用
- Spaans LN, Dijkgraaf MGW, Susa D, et al. Intercostal or Paravertebral Block vs Thoracic Epidural in Lung Surgery: A Randomized Noninferiority Trial. JAMA Surg. 2025. PMID: 40560556. doi:10.1001/jamasurg.2025.1899
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。